• Integration of Embedded Health Solutions (EHS) and HMR Referrals progressing well, driving operational efficiencies and expanding service offerings
• 1H FY25 unaudited revenue for continued operations of $4 million, up 14% over pcp
• 1H FY25 unaudited EBITDA for continued operations $0.4 million (excluding one off costs)

Careteq Limited (ASX: CTQ), a clinical healthtech company specialising in innovative medication management and clinical governance solutions, has provided a quarterly update and commentary on its Appendix 4C for the quarter ending 31 December 2024. The integration of Embedded Health Solutions (EHS) and HMR Referrals continued to progress during the quarter, with the teams operating as one and initiatives actioned to drive growth. The goal is to create a cohesive medication management platform across aged, home, and disability care, which is expected to unlock synergies, streamline services, and support scalable growth. Key operational highlights include increased uptake in Residential Medication Management Reviews (RMMRs) and Home Medicines Reviews (HMRs), supported by the combined pharmacy and GP networks. The rollout of the new integrated operating platform remains on track for Q4 FY25. Careteq continued its focus on strategic growth through targeted business development efforts, with partnerships with key home care providers advancing and new collaboration opportunities identified. The Company's financial position was enhanced during the quarter, with strong cash receipts of $2.3 million and net cash used in operating activities of ($0.1 million). The Company's 1H FY25 unaudited revenue from continued operations is $4 million and underlying EBITDA for continued operations to be $0.4 million (excluding one off costs).

The Company's 1H FY25 unaudited revenue from continued operations is $4 million and underlying EBITDA for continued operations to be $0.4 million (excluding one off costs).

The Company (now consisting of EHS and HMR Referrals) is trading well and ahead of budget YTD with reviews, revenue and EBITDA growth expected in FY25. Key priorities for the coming quarter include finalising the integrated operating platform rollout, expanding strategic partnerships, and scaling operations to meet increasing demand in the aged care and home care sectors.